The core business showed meaningful operational improvement with higher sales, better margins, and positive operating income, but the net loss persists due to one-time write-downs. Traders should monitor the Q1 2026 results to see if margin expansion and volume gains are sustainable, and whether the shift in strategy toward First Defense® is driving organic growth.
Price Chart
Executive Summary
ImmuCell reported a 4.3% increase in 2025 product sales to $27.6 million and a significant improvement in gross margin to 41.4% from 30% in 2024, driven by higher volumes and manufacturing efficiencies. Despite a net loss of $1.0 million, down from $2.2 million in 2024, the results were impacted by $3.6 million in non-recurring charges, including asset and inventory write-downs, while operating income turned positive at $1.6 million.
Key Financial Metrics
Key Facts
- 2025 product sales increased 4.3% to $27.6 million from $26.493 million in 2024
- Gross profit margin improved to 41.4% in 2025 from 30% in 2024
- Net loss narrowed to $1.0 million in 2025 from $2.2 million in 2024
- Non-recurring charges in 2025 totaled $3.6 million, including a $2.7 million Re-Tain® asset write-down and $651,000 in colostrum inventory write-downs
- Net operating income turned positive at $1.6 million in 2025 vs. $1.64 million operating loss in 2024
- Cash and cash equivalents remained flat at $3.8 million; net working capital increased to $13.0 million
Financial Impact
Revenue increased by $1.15 million; gross profit increased by $3.5 million despite a $1.0 million net loss due to large non-recurring charges
Risk Factors
- Material non-recurring charges ($3.6 million) mask underlying performance and raise concerns about asset valuation and inventory management
- Stockholders' equity declined slightly to $27.1 million despite improved operations
- Ongoing reliance on one-time items could signal underlying volatility in earnings quality
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249727 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $10.79 $10.45 | ▼ −3.15% | ▼ −2.00% | $10.24 (−5.10%) |
May 8, 2026 24w ago | 8-K | $8.45 $9.91 | ▲ +17.28% | ▲ +17.36% | $10.24 (+21.18%) |
Apr 8, 2026 28w ago | 8-K | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.24 (+42.42%) |
Apr 8, 2026 28w ago | Press Release | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.24 (+42.42%) |
Mar 4, 2026 33w ago | 8-K | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.24 (+61.26%) |
Mar 4, 2026 33w ago | Press Release | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.24 (+61.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers